Nurix Therapeutics, Roche partner to co-develop BTK degrader bexobrutideg in deal worth up to $2.3 billionPUBT·Jul 21 at 03:01 PMNRIX-1.52%RHHBY+1.45%
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% UpsideTradingView·Jul 16 at 11:20 PMNRIX-1.52%
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.5, Implies 32% UpsideTradingView·Jul 10 at 05:20 PMNRIX-1.52%
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.25, Implies 31% UpsideTradingView·Jul 10 at 11:20 AMNRIX-1.52%
Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.12, Implies 30% UpsideTradingView·Jul 10 at 02:20 AMNRIX-1.52%
Nurix Therapeutics (NASDAQ:NRIX) Releases Quarterly Earnings ResultsMarket Beat·Jul 9 at 03:26 PMNRIX-1.52%
Nurix Therapeutics 3Q 2026: Revenue $9.04M, EPS $(0.81) — 10-Q SummaryTradingView·Jul 9 at 03:21 PMNRIX-1.52%PFE-0.16%
Nurix Therapeutics GAAP EPS of -$0.81 misses by $0.08, revenue of $9.04M misses by $6.25Mbusinessinsider·Jul 9 at 03:15 PMNRIX-1.52%
Nurix Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 9.043 MEarnings Watch·Jul 9 at 03:11 PMNRIX-1.52%
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year High - What's Next?Market Beat·Jul 9 at 11:40 AMNRIX-1.52%
